Abstract: The continuous identification of molecular changes deregulating critical pathways in pancreatic tumor cells provides us with a large number of novel candidates to engineer gene-targeted approaches for pancreatic cancer treatment. Targets—both protein coding and non-coding—are being exploited in gene therapy to influence the deregulated pathways to facilitate cytotoxicity, enhance the immune response or sensitize to current treatments. Delivery vehicles based on viral or non-viral systems as well as cellular vectors with tumor homing characteristics are a critical part of the design of gene therapy strategies. The different behavior of tumoral versus non-tumoral cells inspires vector engineering with the generation of tumor selective products that can prevent potential toxic-associated effects. In the current review, a detailed analysis of the different targets, the delivery vectors, the preclinical approaches and a descriptive update on the conducted clinical trials are presented. Moreover, future possibilities in pancreatic cancer treatment by gene therapy strategies are discussed.
Keywords: viral and non-viral vectors; oncolysis; gene delivery routes; clinical trials
Export to BibTeX
MDPI and ACS Style
Fillat, C.; Jose, A.; Bofill-De Ros, X.; Mato-Berciano, A.; Maliandi, M.V.; Sobrevals, L. Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems. Cancers 2011, 3, 368-395.
Fillat C, Jose A, Bofill-De Ros X, Mato-Berciano A, Maliandi MV, Sobrevals L. Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems. Cancers. 2011; 3(1):368-395.
Fillat, Cristina; Jose, Anabel; Bofill-De Ros, Xavier; Mato-Berciano, Ana; Maliandi, Maria Victoria; Sobrevals, Luciano. 2011. "Pancreatic Cancer Gene Therapy: From Molecular Targets to Delivery Systems." Cancers 3, no. 1: 368-395.